Christopher Mutz - 12 Feb 2025 Form 4 Insider Report for ANI PHARMACEUTICALS INC (ANIP)

Reporting relationship: HEAD OF RARE DISEASE
Issuer ticker: ANIP
Reported as of: 12 Feb 2025
Net transaction value: -$156,550
SEC form: 4
Accepted by SEC: 18 Feb 2025, 20:17:30 UTC
Prior SEC filing: 18 Nov 2024
Next SEC filing: 04 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Christopher Mutz, by attorney-in-fact Meredith W. Cook

Filing notes and source

Key filing fact

Christopher Mutz filed Form 4 for ANI PHARMACEUTICALS INC (ANIP) on 18 Feb 2025.

Key facts

This page summarizes Christopher Mutz's Form 4 filing for ANI PHARMACEUTICALS INC (ANIP).
4 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 18 Feb 2025, 20:17.

Change

Previous filing in this sequence was filed on 18 Nov 2024.
Current net transaction value: -$156,550.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ANIP transaction

Common Stock

Award

Transaction value: $0
Shares: +24,808
Change %: +32%
Price: $0.000000
Shares after: 101,585
Date: 12 Feb 2025
Ownership: Direct
Footnotes: F1

ANIP transaction

Common Stock

Award

Transaction value: $0
Shares: +16,538
Change %: +16%
Price: $0.000000
Shares after: 118,123
Date: 12 Feb 2025
Ownership: Direct
Footnotes: F2

ANIP transaction

Common Stock

Tax liability

Transaction value: $86,789
Shares: -1,473
Change %: -1.2%
Price: $58.92
Shares after: 116,650
Date: 14 Feb 2025
Ownership: Direct
Footnotes: F3

ANIP transaction

Common Stock

Tax liability

Transaction value: $69,761
Shares: -1,184
Change %: -1%
Price: $58.92
Shares after: 115,466
Date: 15 Feb 2025
Ownership: Direct
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 12, 2025.

Footnote F2

These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

Footnote F3

Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,697 shares of restricted stock, the grant of which was previously reported.

Footnote F4

Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,034 shares of restricted stock, the grant of which was previously reported.